DTC
NKTR icon

Deep Track Capital’s Nektar Therapeutics NKTR Stock Holding History

Deep Track Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-33,333
Closed -$2.69M – 56
2022
Q1 		$2.69M Hold
33,333
– – 0.17% 49
2021
Q4 		$6.75M Buy
+33,333
New +$7.23M 0.48% 47

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Deep Track Capital's NKTR Position: Q1 2025 in Review

Deep Track Capital sold out of Nektar Therapeutics (NKTR) in Q1 2025, closing a stake of 131,733 shares — an estimated $1.84M sold.

Deep Track Capital first reported a position in NKTR in Q1 2023 and held it in 8 quarters. The position peaked at $22.2M in Q2 2024. 154 funds tracked by Wall St. Rank hold NKTR as of Q1 2025.

  • Deep Track Capital reported no remaining Nektar Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Deep Track Capital sold 131,733 Nektar Therapeutics shares in Q1 2025, an estimated $1.84M.
  • Deep Track Capital first reported a position in Nektar Therapeutics in Q1 2023 and held it in 8 quarters.
  • Deep Track Capital's Nektar Therapeutics position peaked at $22.2M in Q2 2024.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2025.

Based on Deep Track Capital's 13F filing for Q1 2025, filed 15 May 2025.